Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Adaptimmune Ther ADR (ADAP)

Adaptimmune Ther ADR (ADAP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 249,293
  • Shares Outstanding, K 246,825
  • Annual Sales, $ 60,280 K
  • Annual Income, $ -113,870 K
  • 60-Month Beta 2.44
  • Price/Sales 4.30
  • Price/Cash Flow N/A
  • Price/Book 11.14
Trade ADAP with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -145.13%)
  • Historical Volatility 80.48%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 903.08% on 12/01/23
  • IV Low 0.00% on 05/24/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 53
  • Volume Avg (30-Day) 247
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 13,994
  • Open Int (30-Day) 13,251

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.13
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.17
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +38.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0100 +3.96%
on 05/24/24
1.3400 -21.64%
on 05/16/24
-0.0300 (-2.78%)
since 04/24/24
3-Month
0.8721 +20.40%
on 04/18/24
2.0500 -48.78%
on 03/08/24
-0.4300 (-29.05%)
since 02/23/24
52-Week
0.4200 +150.00%
on 11/28/23
2.0500 -48.78%
on 03/08/24
-0.1500 (-12.50%)
since 05/24/23

Most Recent Stories

More News
Adaptimmune Reports Q1 2024 Financial and Business Updates

Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024Commercial and manufacturing infrastructure...

ADAP : 1.0500 (+3.96%)
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approvalPhiladelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile...

ADAP : 1.0500 (+3.96%)
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell...

ADAP : 1.0500 (+3.96%)
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchiseUpdate on afami-cel launch plans to be provided at the April 18th...

ADAP : 1.0500 (+3.96%)
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell...

ADAP : 1.0500 (+3.96%)
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024Confirmatory evidence for afami-cel full approval agreed with...

ADAP : 1.0500 (+3.96%)
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ:...

ADAP : 1.0500 (+3.96%)
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with...

ADAP : 1.0500 (+3.96%)
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade Philadelphia, Pennsylvania and Oxford,...

ADAP : 1.0500 (+3.96%)
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be up to $400 million BLA submitted in 2023 for afami-cel; projected...

ADAP : 1.0500 (+3.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 1.1367
2nd Resistance Point 1.1033
1st Resistance Point 1.0767
Last Price 1.0500
1st Support Level 1.0167
2nd Support Level 0.9833
3rd Support Level 0.9567

See More

52-Week High 2.0500
Fibonacci 61.8% 1.4273
Fibonacci 50% 1.2350
Last Price 1.0500
Fibonacci 38.2% 1.0427
52-Week Low 0.4200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar